Nicotine replacement therapy,
does it really help with Improved long-term smoking-cessation success?
research showsNicotine replacement therapy is rated A because it strongly and consistently improves abstinence at six months or longer. The Cochrane review identified 136 trials, with 133 trials and 64,640 participants in the main comparison; the risk ratio versus placebo or no NRT was 1.55 (95% CI 1.49 to 1.61), with high-certainty evidence. Gum and patches were each positive, and low-risk-of-bias analyses preserved the conclusion, satisfying independence, replication, and direct-endpoint criteria. NRT differs in ingredient and mechanism from varenicline in verdict 633, and the added contributions of combination NRT and behavioral support are separated.
ads claimMarketing can imply that gum or patches automatically produce abstinence. The evidence shows an increased average probability of success, while correct technique, behavioral support, and combination treatment when appropriate shape outcomes.
Useful facts when choosing a product
- NRT supplies therapeutic nicotine through gum or a patch more slowly than smoking and reduces craving and withdrawal without continued exposure to tobacco smoke.
- A patch provides steady nicotine while gum can address breakthrough cravings, and combining the two improves long-term quit rates over one formulation.
- Behavioral counseling is not required for an NRT effect, but it improves quit planning, trigger management, relapse coping, and adherence and can raise overall success.
- Gum must be chewed and parked as directed, while patch users with skin reactions, vivid dreams, or sleep disturbance should adjust site or wear time according to the label.
What the research actually shows
Hartmann-Boyce 2018 synthesized randomized trials in smokers motivated to quit and found an RR of 1.55 for abstinence at six months or longer. Theodoulou 2023 reviewed 68 trials with 43,327 participants and found high-certainty evidence that a patch plus fast-acting NRT such as gum or a lozenge improved long-term abstinence over one formulation (RR 1.27, 95% CI 1.17 to 1.37). NRT delivers nicotine slowly without tobacco-smoke toxicants to reduce craving and withdrawal and differs from varenicline, a partial nicotinic-receptor agonist.
Why this is classified as A (90)
The direct endpoint of abstinence at six months or longer had an RR of 1.55 (95% CI 1.49 to 1.61) across 133 trials and 64,640 participants, with formulation consistency, robustness in analyses restricted to low-risk-of-bias trials, and extensive generic independent replication. The effect is smaller than varenicline's approximately 2.3 risk ratio, but the greater evidence volume and independence place NRT two points above the A-88 varenicline verdict, at A with 90 points. Added effects of combination NRT and behavioral support are attributed separately; irritation, insomnia, palpitations, and skin reactions remain separate safety issues.
Counterpoint. Persistent cravings on one formulation may justify a patch plus fast-acting gum after checking contraindications and directions. Pregnancy, a recent cardiovascular event, arrhythmia, or adolescent use warrants clinical advice.
Rejudgment record. New verdict — Applied A because high-certainty Cochrane evidence from 136 trials consistently improved abstinence at six months or longer across formulations, support intensities, and analyses restricted to low-risk-of-bias trials, with very strong generic independent replication. The 90-point score reflects a smaller effect than varenicline while retaining a two-point advantage for evidence volume and independence, with combination NRT and behavioral support attributed separately
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Long-term abstinence at six months or longer with gum or patch NRT | A | The high-certainty direct endpoint across 133 trials and 64,640 participants had an RR of 1.55 with consistent formulation-specific and sensitivity analyses. |
| Added contribution of combination NRT and behavioral support | A | High-certainty evidence shows that combination NRT improves long-term abstinence over one formulation, while behavioral support is a separate contributor. |
| Short-term relief of withdrawal and craving | B | Randomized signals exist, but symptoms are subjective and less direct than long-term abstinence. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Hartmann-Boyce J et al. 2018 Cochrane review | Systematic review and meta-analysis of randomized trials | 64,640 | Cochrane Tobacco Addiction Group and academic research; one author disclosed involvement in an included NRT trial | Smoking abstinence after at least six months, biochemically validated when available | The abstinence RR was 1.55 for any NRT (95% CI 1.49 to 1.61), 1.49 for gum, and 1.64 for patches; certainty was high. | Key large direct long-term efficacy evidence |
| Theodoulou A et al. 2023 Cochrane review | Systematic review of randomized comparisons of NRT formulations, doses, and durations | 12,169 | Public and nonprofit support including the United Kingdom NIHR and Cancer Research UK | Abstinence at six months or longer plus cardiac and serious adverse events | A patch plus fast-acting NRT improved long-term quit rates over one formulation (RR 1.27, 95% CI 1.17 to 1.37; high certainty). | Evidence for combination-treatment attribution |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Nicotine replacement therapy x improved long-term smoking-cessation success — Evidence Grade A·90. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/general/nicotine-replacement-therapy-long-term-smoking-cessation/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.